Cancer treatment reports
-
Cancer treatment reports · Mar 1987
Randomized Controlled Trial Clinical TrialSecond-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
A total of 205 women with stage III or IV ovarian cancer who had persistent disease after initial treatment with doxorubicin and cisplatin were randomized to receive melphalan (8 mg/m2 orally for 4 days) or the combination of melphalan (6 mg/m2 for 4 days) and hexamethylmelamine (120 mg/m2 for 14 days) every 4 weeks. Only one of 64 patients with measurable disease had an objective response. ⋯ Neither of these regimens provided effective therapy for women whose disease was not eliminated by first-line treatment. However, the superior results obtained in one subgroup with the addition of hexamethylmelamine suggest that the place of this agent in treating ovarian cancer should be carefully evaluated.
-
Cancer treatment reports · Aug 1986
Case Reports Randomized Controlled Trial Clinical TrialPulmonary toxicity of carmustine in patients treated for malignant glioma.
Carmustine (BCNU) was employed as the only chemotherapeutic agent in a Radiation Therapy Oncology Group multimodality study comparing misonidazole-radiosensitized radiation therapy to conventional radiation therapy in 318 patients with malignant glioma. In 289 patients evaluable for BCNU pulmonary toxicity, there were no clinical manifestations of toxicity in patients receiving less than 902-mg/m2 total BCNU dose. ⋯ Results of a multivariate regression analysis of risk factors, which corrects for survival time bias, suggested increased risk of pulmonary toxicity when total dose exceeds 1400 mg/m2. The risk of pulmonary toxicity was not increased by the administration of misonidazole and does not appear to be related to age.
-
Cancer treatment reports · Jul 1985
Randomized Controlled Trial Clinical TrialAction of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.
A 14-day, randomized, double-blind crossover trial was carried out comparing an oral glucocorticoid, methylprednisolone (MP), against placebo for the relief of pain and other symptoms in 40 terminally ill cancer patients. After the 14-day, double-blind phase was completed, all patients were given MP for 20 days. The daily dose of MP was 32 mg, and end points of the study were pain, psychiatric status, appetite, nutritional status, daily activity, and performance. ⋯ MP was preferred over placebo by 23 of the 31 patients (74%), and, in 22 of the 31 cases (71%), the investigator chose MP over placebo. No serious toxicity was found at the dose of MP used. It is concluded that MP increases the comfort of terminally ill cancer patients.
-
Cancer treatment reports · Dec 1984
Randomized Controlled Trial Comparative Study Clinical TrialCisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Thirty-three patients with advanced-stage ovarian adenocarcinomas, with no prior chemotherapy, were treated with weekly cisplatin (DDP) for four courses followed by five monthly courses of one of two randomly assigned multidrug combinations. These combinations were high-dose methotrexate-leucovorin plus cyclophosphamide (MECY) or cyclophosphamide, hexamethylmelamine, doxorubicin, and DDP (CHAD). Patients with no clinically measurable disease after 6 months of therapy were evaluated by laparoscopy. ⋯ The high negative second-look rate with DDP-MECY is exciting. Positive cytologic washings at the 6-month laparoscopic evaluation were highly predictive that residual disease would be found at the 1-year second-look surgery. Only one patient with positive peritoneal cytology after 6 months of treatment was found to have a negative second-look after 1 year of therapy.
-
Cancer treatment reports · Aug 1980
Randomized Controlled Trial Comparative Study Clinical TrialRandomized comparison of two combination chemotherapy regimens containing doxorubicin in patients with metastatic breast cancer: a Western Cancer Study Group trial.
Ninety-six patients with metastatic breast cancer were entered in a prospectively randomized trial comparing a five-drug doxorubicin (Adriamycin)-containing regimen given in two different schedules. Both regimens included cyclophosphamide, methotrexate, 5-FU, prednisone, and doxorubicin. On one schedule, referred to as "combination" treatment, doxorubicin was given every 21 days and cyclophosphamide was given daily. ⋯ Response frequency and survival were comparable among patients receiving either regimen. Significantly less (P < 0.05) nausea and leukopenia occurred on the fixed-rotation schedule. Therefore, similar therapeutic benefit along with decreased toxicity was obtained by use of combination chemotherapy involving doxorubicin and cyclophosphamide given in the less intensive schedule.